Evidence map›Paper›PMID 41087321›Full record

ArticleJournal of the American Chemical Society2025

Anfinsen Redux: Ribonuclease Folding in the Single-Molecule Regime.

Arek V Melkonian, Evans C Wralstad, Ronald T Raines, David R Walt

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arek V MelkonianHarvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0009-0000-7804-647X
Evans C WralstadDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-2281-7594
Ronald T RainesDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-7164-1719
David R WaltHarvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0002-5524-7348

Funding

RIBONUCLEASES IN CANCER THERAPYR01CA073808 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1997 to 2024
$7.3M
Oncopathology Training ProgramT32CA251062 · NCI · DANA-FARBER CANCER INST · PI JON C. ASTER, KATHLEEN H BURNS · 2020 to 2026
$2.4M
Protein ChemistryR35GM148220 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Ronald T Raines · 2023 to 2026
$2.2M
NCI NIH HHS R01 CA073808NCI NIH HHS T32 CA251062NIGMS NIH HHS R35 GM148220
6 · The paper itself

Abstract

Ribonuclease A (RNase A) has long been known to spontaneously refold to its native conformation and recover catalytic activity following denaturation. Yet, the molecular heterogeneity of its folding pathway has remained unclear due to ensemble averaging in traditional bulk measurements. Here, we use single-molecule enzymology (SME) to monitor the catalytic recovery of urea-denatured RNase A at the single-molecule level. We directly observe that individual RNase A molecules exhibit either fast or slow refolding kinetics, indicating distinct renaturation pathways that implicate slow prolyl peptide bond isomerization. These findings establish the utility of SME in revealing hidden heterogeneity in protein folding pathways.

Indexed as

Ribonuclease, PancreaticSingle Molecule ImagingProtein DenaturationProtein FoldingUreaRibonuclease, PancreaticUrea

Identifiers

PMID41087321
PMCPMC12743634

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.